

ClinicalTrials.gov Search Results 08/01/2022

	Title	Status	Study Results	Conditions	Interventions	Locations
1	MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma	Completed	Has Results	<ul style="list-style-type: none"> •Diffuse Intrinsic Pontine Glioma 	<ul style="list-style-type: none"> •Drug: Panobinostat Nanoparticle Formulation MTX110 •Drug: Convection-Enhanced Delivery (CED) 	<ul style="list-style-type: none"> •University of California, San Francisco, San Francisco, California, United States
2	ABI-009 (Nab-rapamycin) in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma	Active, not recruiting	No Results Available	<ul style="list-style-type: none"> •High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma 	<ul style="list-style-type: none"> •Drug: ABI-009 •Drug: Bevacizumab •Drug: Temozolomide •Drug: Lomustine •Radiation: Radiation •Drug: Marizomib 	<ul style="list-style-type: none"> •St. Joseph Heritage Healthcare, Fullerton, California, United States •Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States •John Wayne Cancer Institute, Santa Monica, California, United States
3	CED of MTX110 Newly Diagnosed Diffuse Midline Gliomas	Recruiting	No Results Available	<ul style="list-style-type: none"> •Diffuse Intrinsic Pontine Glioma •Diffuse Pontine and Thalamic Gliomas •Diffuse Midline Glioma 	<ul style="list-style-type: none"> •Drug: Infusate with MTX110 and gadolinium •Device: Convection-Enhanced Delivery (CED) 	<ul style="list-style-type: none"> •Columbia University Irving Medical Center, New York, New York, United States
4	A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas	Completed	No Results Available	<ul style="list-style-type: none"> •Glioblastoma •Gliosarcoma •Anaplastic Astrocytoma •Anaplastic Oligodendroglioma 	<ul style="list-style-type: none"> •Drug: Nanoliposomal CPT-11 	<ul style="list-style-type: none"> •University of California, San Francisco, San Francisco, California, United States
5	Assessing Dynamic Magnetic Resonance (MR) Imaging in Patients With Recurrent High Grade Glioma Receiving Chemotherapy	Terminated	No Results Available	<ul style="list-style-type: none"> •Brain Neoplasms 	<ul style="list-style-type: none"> •Drug: Ferumoxytol 	<ul style="list-style-type: none"> •Oregon Health & Science University, Portland, Oregon, United States
6	AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma	Recruiting	No Results Available	<ul style="list-style-type: none"> •Glioblastoma 	<ul style="list-style-type: none"> •Drug: Polysiloxane Gd-Chelates based nanoparticles (AGuIX) •Radiation: radiotherapy •Drug: Temozolomide 	<ul style="list-style-type: none"> •CHU de Brest, Brest, France •Centre Jean Perrin, Clermont-Ferrand, France •CHU de Grenoble, Grenoble, France •Centre Léon Berard, Lyon, France •Institut de Cancérologie de l'Ouest, Saint Herblain, France •Institut de Cancérologie Strasbourg Europe, Strasbourg, France
7	NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery	Completed	No Results Available	<ul style="list-style-type: none"> •Gliosarcoma •Recurrent Glioblastoma 	<ul style="list-style-type: none"> •Other: Laboratory Biomarker Analysis •Other: Pharmacological Study •Drug: Targeted Molecular Therapy 	<ul style="list-style-type: none"> •Northwestern University, Chicago, Illinois, United States
8	Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma	Terminated	Has Results	<ul style="list-style-type: none"> •RECURRENT GLIOBLASTOMA 	<ul style="list-style-type: none"> •Genetic: SGT-53 •Drug: Temozolomide 	<ul style="list-style-type: none"> •MD Anderson Cancer Center, Houston, Texas, United States •China Medical University Hospital, Taichung, Taiwan

	Title	Status	Study Results	Conditions	Interventions	Locations
9	9-ING-41 in Patients With Advanced Cancers	Recruiting	No Results Available	<ul style="list-style-type: none"> •Cancer •Pancreatic Cancer •Sarcoma •Renal Cancer •Refractory Cancer •Refractory Neoplasm •Refractory Non-Hodgkin Lymphoma •Pancreatic Adenocarcinoma •Resistant Cancer •Neoplasm Metastasis •and 15 more 	<ul style="list-style-type: none"> •Drug: 9-ING-41 •Drug: Gemcitabine - 21 day cycle •Drug: Doxorubicin. •Drug: Lomustine •Drug: Carboplatin. •Drug: Nab paclitaxel. •Drug: Paclitaxel. •Drug: Gemcitabine - 28 day cycle •Drug: Irinotecan 	<ul style="list-style-type: none"> •Mayo Clinic, Phoenix, Arizona, United States •UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States •Miami Cancer Institute, Miami, Florida, United States •Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, United States •Kansas University Cancer Center, Kansas City, Kansas, United States •University of Michigan, Ann Arbor, Michigan, United States •Rhode Island Hospital, Providence, Rhode Island, United States •Sanford Research, Sioux Falls, South Dakota, United States •Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States •Fred Hutchinson Cancer Research Center, Seattle, Washington, United States •and 3 more
10	A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent Glioblastoma Multiforme (GBM)	Unknown status	No Results Available	<ul style="list-style-type: none"> •Glioblastoma •Astrocytoma, Grade IV 	<ul style="list-style-type: none"> •Drug: EGFR(V)-EDV-Dox 	<ul style="list-style-type: none"> •John Hopkins Hospital, Baltimore, Maryland, United States •Lenox Hill Hospital, Northwell Health, New York, New York, United States